161 related articles for article (PubMed ID: 7907341)
1. Detection of a new apolipoprotein-E mutation in type III hyperlipidemia using deoxyribonucleic acid restriction isotyping.
Walden CC; Huff MW; Leiter LA; Connelly PW; Hegele RA
J Clin Endocrinol Metab; 1994 Mar; 78(3):699-704. PubMed ID: 7907341
[TBL] [Abstract][Full Text] [Related]
2. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/'null' genotype.
Feussner G; Funke H; Weng W; Assmann G; Lackner KJ; Ziegler R
Eur J Clin Invest; 1992 Sep; 22(9):599-608. PubMed ID: 1360898
[TBL] [Abstract][Full Text] [Related]
3. Identification of a new apolipoprotein E variant (E2 Arg142-->Leu) in type III hyperlipidemia.
Richard P; de Zulueta MP; Beucler I; De Gennes JL; Cassaigne A; Iron A
Atherosclerosis; 1995 Jan; 112(1):19-28. PubMed ID: 7772063
[TBL] [Abstract][Full Text] [Related]
4. Identification, molecular characterization, and cellular studies of an apolipoprotein E mutant (E1) in three unrelated families with hyperlipidemia.
Miller DB; Hegele RA; Wolfe BM; Huff MW
J Clin Endocrinol Metab; 1995 Mar; 80(3):807-13. PubMed ID: 7883834
[TBL] [Abstract][Full Text] [Related]
5. Restriction isotyping of apolipoprotein E R145C in type III hyperlipoproteinemia.
Hsia SH; Connelly PW; Hegele RA
J Investig Med; 1995 Apr; 43(2):187-94. PubMed ID: 7735921
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
Feussner G; Albanese M; Mann WA; Valencia A; Schuster H
Eur J Clin Invest; 1996 Jan; 26(1):13-23. PubMed ID: 8682150
[TBL] [Abstract][Full Text] [Related]
7. Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia.
Feussner G; Dobmeyer J; Nissen H; Hansen TS
Am J Med Genet; 1996 Oct; 65(2):149-54. PubMed ID: 8911609
[TBL] [Abstract][Full Text] [Related]
8. Heterozygosity for apolipoprotein E-4Philadelphia(Glu13----Lys, Arg145----Cys) is associated with incomplete dominance of type III hyperlipoproteinemia.
Lohse P; Rader DJ; Brewer HB
J Biol Chem; 1992 Jul; 267(19):13642-6. PubMed ID: 1352296
[TBL] [Abstract][Full Text] [Related]
9. Apo E variants in patients with type III hyperlipoproteinemia.
Civeira F; Pocoví M; Cenarro A; Casao E; Vilella E; Joven J; González J; Garcia-Otín AL; Ordovás JM
Atherosclerosis; 1996 Dec; 127(2):273-82. PubMed ID: 9125318
[TBL] [Abstract][Full Text] [Related]
10. Compound heterozygotes for a novel mutation, apo E1 Nagoya (Arg142Ser) and Apo E2 (Arg158Cys), with severe type III hyperlipoproteinemia and familial hypercholesterolemia.
Sakuma N; Hibino T; Saeki T; Nagata T; Sato T; Okuda N; Matsunaga A; Sasaki J
J Atheroscler Thromb; 2014; 21(9):983-8. PubMed ID: 24953047
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E1 Lys-146----Glu with type III hyperlipoproteinemia.
Moriyama K; Sasaki J; Matsunaga A; Arakawa F; Takada Y; Araki K; Kaneko S; Arakawa K
Biochim Biophys Acta; 1992 Sep; 1128(1):58-64. PubMed ID: 1356443
[TBL] [Abstract][Full Text] [Related]
12. Discovery and consequences of apolipoprotein-epsilon(3Groningen): a G-insertion in codon 95/96 that is predicted to cause a premature stop codon.
Dijck-Brouwer DA; van Doormaal JJ; Kema IP; Brugman AM; Kingma AW; Muskiet FA
Ann Clin Biochem; 2005 Jul; 42(Pt 4):264-8. PubMed ID: 15989726
[TBL] [Abstract][Full Text] [Related]
13. Identification of an apolipoprotein(e) variant associated with type III hyperlipoproteinaemia in an indigenous Australian.
Tate JR; Hoffmann MM; Lovelock PK; Kesting JB; Shaw JT
Ann Clin Biochem; 2001 Jan; 38(Pt 1):46-53. PubMed ID: 11270841
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.
Wardell MR; Brennan SO; Janus ED; Fraser R; Carrell RW
J Clin Invest; 1987 Aug; 80(2):483-90. PubMed ID: 3038959
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein epsilon 2/3 genotype and type III hyperlipoproteinemia among Taiwanese.
Lin HP; Kao JT
Clin Chim Acta; 2003 Apr; 330(1-2):173-8. PubMed ID: 12636937
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of type III hyperlipoproteinemia in Germany.
Feussner G; Feussner V; Hoffmann MM; Lohrmann J; Wieland H; März W
Hum Mutat; 1998; 11(6):417-23. PubMed ID: 9603433
[TBL] [Abstract][Full Text] [Related]
17. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.
Matsunaga A; Sasaki J; Komatsu T; Kanatsu K; Tsuji E; Moriyama K; Koga T; Arakawa K; Oikawa S; Saito T; Kita T; Doi T
Kidney Int; 1999 Aug; 56(2):421-7. PubMed ID: 10432380
[TBL] [Abstract][Full Text] [Related]
18. Identification of variant apolipoprotein E by isoelectric focusing and restriction isotyping in a patient with type III hyperlipoproteinemia.
Nassar BA; McPherson R; Lamothe EM; al-Sultan AI; Zhang ZJ; Rosenblatt DS
Clin Chem; 1991 Jul; 37(7):1308. PubMed ID: 1677318
[No Abstract] [Full Text] [Related]
19. Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia.
Mann WA; Gregg RE; Sprecher DL; Brewer HB
Biochim Biophys Acta; 1989 Oct; 1005(3):239-44. PubMed ID: 2804053
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E-4Philadelphia (Glu13----Lys,Arg145----Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia.
Lohse P; Mann WA; Stein EA; Brewer HB
J Biol Chem; 1991 Jun; 266(16):10479-84. PubMed ID: 1674745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
